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Abstracts
man capital, incidence, and prevalence were chosen for
review based on their relevance.
RESULTS: Preliminary results indicate that the published
cost studies available underestimate the "true" costs of
smoking. The most current articles approximate annual
direct medical costs to health care payers of $50 billion
(1993); inflating to 1997 equals $59 billion or $1,200 per
smoker. Although the latest cost studies do not attempt
to estimate indirect costs, past studies have found indirect
costs to be 1.5-2 times the direct costs. Therefore, using
direct and indirect costs we estimate total smoking costs
to be $150 billion (1993); inflating to 1997 equals $176
billion or $3,500 per smoker.
CONCLUSION: Quantifying the cost of smoking is a
difficult task due to tobacco use infiltrating many aspects
of life and the dependency of cost on perspective. Cost-
of-illness studies provide cost estimation data which can
be useful in aiding decision-makers who are allocating
health care resources.
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LIPID THERAPY AND CARDIOVASCULAR
DISEASE: HOW MANY AMERICANS
SHOULD BE TREATED?
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Recent lipid therapy clinical trials confirm the treatment
recommendations of the National Cholesterol Education
Program (NCEP) and extend the proven benefits of pri-
mary and secondary prevention to women, elderly, and
high risk patients with average cholesterol.
OBJECTIVE: The purpose of this study was to estimate
and compare the size of the primary and secondary pre-
vention population if lipid treatment recommendations
were based on (1) the NCEP treatment guidelines and the
baseline characteristics of (2) the primary prevention
population in the West of Scotland Coronary Prevention
Study (WOSCOPS) and the Air Force/Texas Coronary
Atherosclerosis Prevention Study (AFCAPS), (3) the sec-
ondary prevention population in the Cholesterol and Re-
current Events (CARE) trial, and the Scandinavian Sim-
vastatin Survival study (4S).
METHODS: Phase 1 data from the third National
Health and Nutrition Examination Survey were used for
analysis.
RESULTS: Following the current NCEP recommenda-
tions, 18.6 and 5.8 million adults would be candidates
for primary prevention and secondary prevention inter-
vention, respectively. If the treatment guidelines were
based on the characteristics of the WOSCOPS or AF-
CAPS patients, the size of the primary prevention popula-
tion would increase by 12.2 million to 30.8 million. Ex-
tending the recommendation based on the characteristics
of the CARE or the 4S study patients would increase the
secondary prevention population size by 2 million to 7.8
55
million.
CONCLUSION: Recent clinical trials suggest that more
than 15% of U.S. adults would benefit from lipid-lower-
ing therapy for primary and secondary prevention of
heart disease. Cost-effectiveness evaluation of lipid-low-
ering strategies should be used as a guide to treatment
decisions.
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The impact of acute renal failure (ARF) on cost was evalu-
ated in elderly patients with congestive heart failure (CHF).
METHODS: We reviewed medical records of 2,176 Con-
necticut Medicare beneficiaries, aged 65 and older who
were hospitalized with CHF, excluding CHF due to se-
vere AS, MS, or primary non-cardiac illness, between
January 1994 and December 1995 at 20 hospitals. ARF
was defined as an increase in serum creatinine level of
25% from admission, to at least 2 mg/dL during hospital-
ization. We excluded patients who did not have at least
two creatinine measurements (N = 251). To avoid in-
cluding patients with ARF as a result of procedures or
complications, we excluded all patients with major com-
plications or procedures during hospitalization (n =
531). Linear regression models were used to examine the
relationship between ARF and length of hospital stay and
hospital cost.
RESULTS: A total of 1,681 patients were included in the
study sample. Of those, 164 (10%) developed ARF dur-
ing hospitalization. After adjusting for confounding ef-
fects of sex, age, history of CHF, history of hypertension,
diabetes, rales, hematocrit, creatinine, systolic blood
pressure, and left ventricular ejection fraction, ARF was
associated with a significant increase in the length of stay
(LOS) by 3.31 days (p < 0.0001) and a significant in-
crease in hospital cost by $2,714 (p < 0.0001).
CONCLUSION: ARF in hospitalized older patients with
CHF is associated with a longer LOS and higher cost.
Strategies to prevent the development of ARF in high-risk
hospitalized patients may provide the opportunity for
marked reductions in cost.
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OBJECTIVE: To calculate the cost of heart failure in Bel-
gium, based on an epidemiological model.
